Kerato: Vision, Strategy and Growth Plans

In this interview, Sarah Greenhalgh, Managing Director of Kerato, explains how the company is tackling the global challenge of corneal blindness - a leading cause of vision impairment worldwide.

Kerato is developing a simple, elegant regenerative solution designed to repair the corneal surface and reduce reliance on donor transplants.

The opportunity:

• Corneal transplants are one of the most common tissue transplants globally

• There is a severe and growing shortage of donor corneas

• Only around 1 in 70 patients who require a transplant currently receive one

• Access is highly unequal depending on geography

Kerato’s solution:

• A product that facilitates the eye’s natural ability to heal itself

• Designed to address corneal surface damage without donor tissue

• Successfully completed preclinical (animal) testing

• Demonstrated proof of concept

Commercial strategy:

• Initial focus on the animal health market

• Veterinary trials scheduled to begin in early 2026

• Data generated will de-risk progression into human clinical applications

This positions Kerato to address a significant unmet medical need while building long-term value through staged commercialisation and regulatory de-risking.